Cargando…

“Cerberus” T Cells: A Glucocorticoid-Resistant, Multi-Pathogen Specific T Cell Product to Fight Infections in Severely Immunocompromised Patients

Adoptive immunotherapy (AI) with pathogen-specific T cells is a promising alternative to pharmacotherapy for the treatment of opportunistic infections after allogeneic hematopoietic cell transplantation or solid organ transplantation. However, clinical implementation of AI is limited to patients not...

Descripción completa

Detalles Bibliográficos
Autores principales: Koukoulias, Kiriakos, Papayanni, Penelope-Georgia, Georgakopoulou, Aphrodite, Alvanou, Maria, Laidou, Stamatia, Kouimtzidis, Anastasios, Pantazi, Chrysoula, Gkoliou, Glykeria, Vyzantiadis, Timoleon-Achilleas, Spyridonidis, Alexandros, Makris, Antonios, Chatzidimitriou, Anastasia, Psatha, Nikoletta, Anagnostopoulos, Achilles, Yannaki, Evangelia, Papadopoulou, Anastasia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7848034/
https://www.ncbi.nlm.nih.gov/pubmed/33537032
http://dx.doi.org/10.3389/fimmu.2020.608701
_version_ 1783645042367266816
author Koukoulias, Kiriakos
Papayanni, Penelope-Georgia
Georgakopoulou, Aphrodite
Alvanou, Maria
Laidou, Stamatia
Kouimtzidis, Anastasios
Pantazi, Chrysoula
Gkoliou, Glykeria
Vyzantiadis, Timoleon-Achilleas
Spyridonidis, Alexandros
Makris, Antonios
Chatzidimitriou, Anastasia
Psatha, Nikoletta
Anagnostopoulos, Achilles
Yannaki, Evangelia
Papadopoulou, Anastasia
author_facet Koukoulias, Kiriakos
Papayanni, Penelope-Georgia
Georgakopoulou, Aphrodite
Alvanou, Maria
Laidou, Stamatia
Kouimtzidis, Anastasios
Pantazi, Chrysoula
Gkoliou, Glykeria
Vyzantiadis, Timoleon-Achilleas
Spyridonidis, Alexandros
Makris, Antonios
Chatzidimitriou, Anastasia
Psatha, Nikoletta
Anagnostopoulos, Achilles
Yannaki, Evangelia
Papadopoulou, Anastasia
author_sort Koukoulias, Kiriakos
collection PubMed
description Adoptive immunotherapy (AI) with pathogen-specific T cells is a promising alternative to pharmacotherapy for the treatment of opportunistic infections after allogeneic hematopoietic cell transplantation or solid organ transplantation. However, clinical implementation of AI is limited to patients not receiving high-dose steroids, a prerequisite for optimal T-cell function, practically excluding the most susceptible to infections patients from the benefits of AI. To address this issue, we here rapidly generated, clinical doses of a steroid-resistant T-cell product, simultaneously targeting four viruses (adenovirus, cytomegalovirus, Epstein Barr virus, and BK virus) and the fungus Aspergillus fumigatus, by genetic disruption of the glucocorticoid receptor (GR) gene using CRISPR/CAS9 ribonucleoprotein delivery. The product, “Cerberus” T cells (Cb-STs), was called after the monstrous three-headed dog of Greek mythology, due to its triple potential; specificity against viruses, specificity against fungi and resistance to glucocorticoids. Following efficient on-target GR disruption and minimal off-target editing, the generated Cb-STs maintained the characteristics of pentavalent-STs, their unedited counterparts, including polyclonality, memory immunophenotype, specificity, and cytotoxicity while they presented functional resistance to dexamethasone. Cb-STs may become a powerful, one-time treatment for severely immunosuppressed patients under glucocorticoids who suffer from multiple, life-threatening infections post-transplant, and for whom therapeutic choices are limited.
format Online
Article
Text
id pubmed-7848034
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-78480342021-02-02 “Cerberus” T Cells: A Glucocorticoid-Resistant, Multi-Pathogen Specific T Cell Product to Fight Infections in Severely Immunocompromised Patients Koukoulias, Kiriakos Papayanni, Penelope-Georgia Georgakopoulou, Aphrodite Alvanou, Maria Laidou, Stamatia Kouimtzidis, Anastasios Pantazi, Chrysoula Gkoliou, Glykeria Vyzantiadis, Timoleon-Achilleas Spyridonidis, Alexandros Makris, Antonios Chatzidimitriou, Anastasia Psatha, Nikoletta Anagnostopoulos, Achilles Yannaki, Evangelia Papadopoulou, Anastasia Front Immunol Immunology Adoptive immunotherapy (AI) with pathogen-specific T cells is a promising alternative to pharmacotherapy for the treatment of opportunistic infections after allogeneic hematopoietic cell transplantation or solid organ transplantation. However, clinical implementation of AI is limited to patients not receiving high-dose steroids, a prerequisite for optimal T-cell function, practically excluding the most susceptible to infections patients from the benefits of AI. To address this issue, we here rapidly generated, clinical doses of a steroid-resistant T-cell product, simultaneously targeting four viruses (adenovirus, cytomegalovirus, Epstein Barr virus, and BK virus) and the fungus Aspergillus fumigatus, by genetic disruption of the glucocorticoid receptor (GR) gene using CRISPR/CAS9 ribonucleoprotein delivery. The product, “Cerberus” T cells (Cb-STs), was called after the monstrous three-headed dog of Greek mythology, due to its triple potential; specificity against viruses, specificity against fungi and resistance to glucocorticoids. Following efficient on-target GR disruption and minimal off-target editing, the generated Cb-STs maintained the characteristics of pentavalent-STs, their unedited counterparts, including polyclonality, memory immunophenotype, specificity, and cytotoxicity while they presented functional resistance to dexamethasone. Cb-STs may become a powerful, one-time treatment for severely immunosuppressed patients under glucocorticoids who suffer from multiple, life-threatening infections post-transplant, and for whom therapeutic choices are limited. Frontiers Media S.A. 2021-01-18 /pmc/articles/PMC7848034/ /pubmed/33537032 http://dx.doi.org/10.3389/fimmu.2020.608701 Text en Copyright © 2021 Koukoulias, Papayanni, Georgakopoulou, Alvanou, Laidou, Kouimtzidis, Pantazi, Gkoliou, Vyzantiadis, Spyridonidis, Makris, Chatzidimitriou, Psatha, Anagnostopoulos, Yannaki and Papadopoulou http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Koukoulias, Kiriakos
Papayanni, Penelope-Georgia
Georgakopoulou, Aphrodite
Alvanou, Maria
Laidou, Stamatia
Kouimtzidis, Anastasios
Pantazi, Chrysoula
Gkoliou, Glykeria
Vyzantiadis, Timoleon-Achilleas
Spyridonidis, Alexandros
Makris, Antonios
Chatzidimitriou, Anastasia
Psatha, Nikoletta
Anagnostopoulos, Achilles
Yannaki, Evangelia
Papadopoulou, Anastasia
“Cerberus” T Cells: A Glucocorticoid-Resistant, Multi-Pathogen Specific T Cell Product to Fight Infections in Severely Immunocompromised Patients
title “Cerberus” T Cells: A Glucocorticoid-Resistant, Multi-Pathogen Specific T Cell Product to Fight Infections in Severely Immunocompromised Patients
title_full “Cerberus” T Cells: A Glucocorticoid-Resistant, Multi-Pathogen Specific T Cell Product to Fight Infections in Severely Immunocompromised Patients
title_fullStr “Cerberus” T Cells: A Glucocorticoid-Resistant, Multi-Pathogen Specific T Cell Product to Fight Infections in Severely Immunocompromised Patients
title_full_unstemmed “Cerberus” T Cells: A Glucocorticoid-Resistant, Multi-Pathogen Specific T Cell Product to Fight Infections in Severely Immunocompromised Patients
title_short “Cerberus” T Cells: A Glucocorticoid-Resistant, Multi-Pathogen Specific T Cell Product to Fight Infections in Severely Immunocompromised Patients
title_sort “cerberus” t cells: a glucocorticoid-resistant, multi-pathogen specific t cell product to fight infections in severely immunocompromised patients
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7848034/
https://www.ncbi.nlm.nih.gov/pubmed/33537032
http://dx.doi.org/10.3389/fimmu.2020.608701
work_keys_str_mv AT koukouliaskiriakos cerberustcellsaglucocorticoidresistantmultipathogenspecifictcellproducttofightinfectionsinseverelyimmunocompromisedpatients
AT papayannipenelopegeorgia cerberustcellsaglucocorticoidresistantmultipathogenspecifictcellproducttofightinfectionsinseverelyimmunocompromisedpatients
AT georgakopoulouaphrodite cerberustcellsaglucocorticoidresistantmultipathogenspecifictcellproducttofightinfectionsinseverelyimmunocompromisedpatients
AT alvanoumaria cerberustcellsaglucocorticoidresistantmultipathogenspecifictcellproducttofightinfectionsinseverelyimmunocompromisedpatients
AT laidoustamatia cerberustcellsaglucocorticoidresistantmultipathogenspecifictcellproducttofightinfectionsinseverelyimmunocompromisedpatients
AT kouimtzidisanastasios cerberustcellsaglucocorticoidresistantmultipathogenspecifictcellproducttofightinfectionsinseverelyimmunocompromisedpatients
AT pantazichrysoula cerberustcellsaglucocorticoidresistantmultipathogenspecifictcellproducttofightinfectionsinseverelyimmunocompromisedpatients
AT gkoliouglykeria cerberustcellsaglucocorticoidresistantmultipathogenspecifictcellproducttofightinfectionsinseverelyimmunocompromisedpatients
AT vyzantiadistimoleonachilleas cerberustcellsaglucocorticoidresistantmultipathogenspecifictcellproducttofightinfectionsinseverelyimmunocompromisedpatients
AT spyridonidisalexandros cerberustcellsaglucocorticoidresistantmultipathogenspecifictcellproducttofightinfectionsinseverelyimmunocompromisedpatients
AT makrisantonios cerberustcellsaglucocorticoidresistantmultipathogenspecifictcellproducttofightinfectionsinseverelyimmunocompromisedpatients
AT chatzidimitriouanastasia cerberustcellsaglucocorticoidresistantmultipathogenspecifictcellproducttofightinfectionsinseverelyimmunocompromisedpatients
AT psathanikoletta cerberustcellsaglucocorticoidresistantmultipathogenspecifictcellproducttofightinfectionsinseverelyimmunocompromisedpatients
AT anagnostopoulosachilles cerberustcellsaglucocorticoidresistantmultipathogenspecifictcellproducttofightinfectionsinseverelyimmunocompromisedpatients
AT yannakievangelia cerberustcellsaglucocorticoidresistantmultipathogenspecifictcellproducttofightinfectionsinseverelyimmunocompromisedpatients
AT papadopoulouanastasia cerberustcellsaglucocorticoidresistantmultipathogenspecifictcellproducttofightinfectionsinseverelyimmunocompromisedpatients